Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure  by Nakamura, Motoyuki et al.
Elevated vascular tone in heart failure has been ~ostolated to
increase nd-systolic pressure in t e diseased ventricle, causing 
an increase in cardiac afterload 
Neurohormonal ctivation, such as sympathetic nerve activity, 
the renin-angiotensin ystem and arginine vasopressin, has been 
suggested asan important contributor to the abnormal vasocon- 
striction observed in heart failure (42). In addition to these 
pathophysiologic mechanisms, attenuation of endothelium- 
dependent vasorelaxation in the peripheral vasculature has re- 
cently been demonstrated in patients with heart failure and in 
animal models of heart failure (3-7). However, it remains un- 
known whether the endothelial dysfunction i heart failure can be 
restored by pharmacologic intervention. 
Angiotensin-converting enzyme inhibitors are widely used 
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for improving the prognosis and lor prcvcnting progression ol
illl failure in patients with chronic heart failure (8-10). 
owever, the mechanisms by which these drugs achieve their 
favorable ffects are not yet completely understood. 
studies (11-13) have demonstrated that angiotensin-converting 
enzyme ir,hibitors augment endothelium-dependent vasodila- 
tion in isolated rat aorta and canine coronary artery. In 
addition, Hirooka et al. (14) reported that oral administration 
of the angiotensin-converting enzyme inhibitor captopril 
enhanced impaired acetylcholine-induced endothelium- 
dependent vasodilation in the forearm vasculature of hyper- 
tensive patients. Furthermore, we recently observed (15) that 
intraarterial coinfusion of the angiotensin-converting e zyme 
inhibitor enalaprilat enhanced endothelium-dependent vasodi- 
lation induced by acetylcholine in the forearm vascular bed of 
healthy volunteers. 
Thus, the aim of the present study was to investigate 
whether angiotensin-converting e zyme inhibitors improve the 
attenuated endothelium-dependent vasodilation i the periph- 
eral vasculature ofpatients with chronic heart failure. We also 
explored the mechanism of the inhibitor-induced potentiation 
of endothelium-dependent vasodilation. 
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Protocol 1 Protocol 2 Protocol 3 - - 
Group 1 Group 2 Group 3 Group 4 Group 5 P 
(II = 8) (n = 12) (n = 10) (n = 10) (n = IO) Value 
Age W 
Gender (F/M) 
Diagnosis 
VHD 
DCM 
CHD 
Hemodynamic variables 
Sl3P (mm Hg) 
HR (bcatdmin) 
CTR (ST) 
PCWP (mm t&) 
Drugs 
Dig 
Fur0 
Porcarm volume (ml) 
52 t 5 57-c 6 62 z 5 
6/2 814 5J5 
llYC4 
6825 
4822 
11323 117 z 5 
62 9 3 65 + 6 
63 ?: 3 67 ?I 5 
1x 2 4 22 L 6 
8 8 
7 9 
732 2: 52 667282 
7 
I 
2 
6 4 
3 3 
1 3 
Data presented arc mean value L+_ SE or number of patients. C D = congcnitsl heart dkasc; CTR - c~r~iot~l~~ra~i~ 
ratio; DCM = dilated cardiomyopathy; Dig = digitalis; F L- female; Fur0 = furoscmide; HR I- heart rate; M = male; 
PCWP = pulmonary capillaty wedge pressure; SBP = systolic blood pressure; V D = aelvular heart disease. 
Subjects. A total of 50 subjects (Table 1) were recruited for 
this study and were assigned to three experimenta! protocols 
(Fig. 1). The first protocol was applied to three groups: 8 
healthy volunteers (group 1) and 22 patients with chronic heart 
failure (groups 2 and 3). The group 1 volunteer were carefully 
evaluated by physical examination, routine blood and urine 
tests, electrocardiogram and chest X-ray film; no ab~or~~a~ities 
were detected. Groups 2 and 3 were distinguished on the basis 
0 e clinical severity of hea 
12 patients (functional classes 
S), and these were assigned to protocols 2 and 3. respectively. 
FBF b eb b 0 ebbcc b@b8 bobeb cbeb* 
Blood . . 
Protocol 2 Protocol 3 
ao0.a ee0.a eo 0 e e baeebbebbebbbbb 
1. Study protocols. Proto- 
consisted of five drug regi- 
raarterial infusions of 
troprusside (SNP) and 
ne (ACh) were first per- 
formed with placebo (PL), fol- 
lowed by infusions ofthe angioten- 
sin-converting enzyme inhibitor 
enalaprilat (CEI) alone, and then 
CEI was administered with sodium 
nitroprusside and acetylcholine. 
Blood samples were obtained be- 
fore and after enalaprilat infusion. 
Forearm blood flow (FBF) re- 
sponse to acetylcholine alone was 
calibrated in another set of patients 
who were randomized to Protocols 
2 and 3. Protocol 2consisted of two 
acetyicholine infusions with and 
without enalaprilat fter pretreat- 
ment with NG-mon L- 
arginine (~~~~~~). 3 
consisted of preadministration of 
acetylsalicylic acid (ASA) followed 
by two acetylcholine fusions with 
placebo r enalaprilat. 
n the 43 patients with heai.: I.H~UILL the etiology was 
[311111ELil ’3hC disease in i 
at the time of the 
in Silastic strain gauge 
circulation was excluded by of a wrist cu 
ssure. The upper arm co 
ow curves for each recording period were analyzed by a 
computer-assisted digital board, and the mean values were 
used for statistical analysis. 
cols used in this 
light meal and was performed in a quiet, air-conditioned room. 
Baseline blood flow was recorded for all subjects, and a 
minimal recovery period of 20 min was interposed between 
experimental infusions to allow the blood flow to return to 
basal values. For the first study protocol, sodium nitroprusside 
was infused in four graded doses (0.025, 0.05, 0.10 and 
0.15 &min per 100 ml tissue, each for 2 min) by a constant- 
rate infusion pump (Terumo STC-521, Tokyo, Japan). Physi- 
ologic saline solution at a volume of 0.2 ml/min was coinfused 
as a placebo through another infusion pump with a three-way 
stopcock. After blood flow had returned to the basal value, 
acetylcholine was infused in four incremental doses (0.75. 1.5, 
3.0 and 4.5 CLglmin per 100 ml tissue, each for 2 mitt) with a 
placebo coinfusion. The: aim of the third regimen in this 
protocol was to determine whether an angiotendn-converting 
enzyme inhibitor alone would affect blood flow. Enalaprilat 
(Merck, Sharp & Dohme) was administered atthree incremen- 
tal rates of 0.15, 0.30 and 0.60 pg/min per 100 ml tissue. In 
e second and third 
easureme~t of plasma renin 
e and enalaprijat concentra- 
protoco 
alone were analyzed by one-way ANOVA with repeated 
~~ea~~lrerne~ts. P arson’s correlation coefficrents were used to 
examine the relations between the maximal effect of the 
a~l~iotcnsin-convertil~g enzyme inhibitor on forearm bloo 
line characteristics. Data are presented as mea 
values arc two-tailed, and p < 
0.05 was considered s~gI~~~cal~t. 
no significant differences in gender, etiology of heart failure. 
systolic blood pressure, heart rate, cardiothoracic rate or 
treatment among the patient groups (Table 1). Flowever, hasal 
forearm blood flow in patients with heart failure was signifi- 
cantly lower than that in healthy control subjects (group 1, 
3.0 & 0.04; group 2, 1.8 + 0.3; group 3, 1.5 $_ 0.4 ml/min per dl 
ern~dy~~~m~c ~~i~~~~s. The expertment 
lat did not have any significant effect on basal forearm blood 
flow (group 1, from 3.0 -4 0.4 to 3.4 t 0.4: group 2, from 1.8 4 
0.3 to 2.0 !I 0.4; group 3, from 1.5 + 0.4 to 1.7 2 0.6 ml/min 
per dl tissue), systemic arterial hlood pressure (group 1, from 
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Table 2. Plasma Renin Activk,, Plasma Norepinephrine Concentration and Plasma Enalaprilat Concentration Before and After 
A&ninkation of the Arqioteosin-Converting Enzyme Inhibitor Enalaprilat 
Group 1 Group 2 Group 3 
Before A!‘et Before Alter Before After 
Plasma renin activity (AI n@nl per h) 1.3 k 0.4 1.3 + 0.5 1.6 t 0.7 1.9 2 0.8 2.7 ? 0.9 2.9 t 1.1 
playma nofepinepbnnc (@ml) 200190 2iBrbO 25OZ80 270 f 50 380 z 100 410-c 110 
Plasma enalaprilat (@ml) ND 44.2 + 13.4’ ND 73.5 + 15.1* ND 84.5 2 30.40 
1.5 + 0.3t 3.0 r 0.H 3.7 2 1.3f 
Data presented are mean value t SE. Nc significant changes in plasma renin activity and plasma norepinepbrine level were observed after ~d~~iflis~~~~i~~ of the 
an&tein-converting enzyme inhibitor. Blood samples were obtained from the experimental arm (*) and contralateral arm (T). AI = angiotensin 1. 
~~9;:4to115~6;group2,from113~3to111-+ 
3, from 117 2 5 to 115 1 5 mm Hg) or heart rate (
from 69 + 5 to 68 L: 4; group 2, from 62 t 
3, from 65 ?: 6 to 66 ?z 7 ~ats/m~n). 
concentrations in the experimental arm were clearly elevated 
Infusion of a~etylcb~l~ne 
rm blood flow in a dose- 
dependent manner in all groups. When a fixed dose of 
enalaprilat (0.60 pg/min per 100 ml tissue) was coinfused with 
the incremental infusion of acetylcholine, blood flow increased 
significantly in groups 1 and 2 (group 1 p < 0.01; group 2 p < 
0.05, two-way ANOVA with repeated measurements) (Fig. 2). 
However, this augmentation effect was not observed in group 3 
(Fig. 2). in contrast, nitroprusside-induced changes inforearm 
blood flow were not affected by coinfusion 
lary wedge pressure (r = 0.12). 
tment dtb ~-monome~yl=~- 
n of p-monomethyl+arginine, 
arm blood flow response to acetylcholine was significantly 
reduced in group 4 (p < 0.01) (Fig. 4). Pretreatment with 
p-monomethyl-t=arginine failed to block the augmentative 
effect Qf the acetykholine-induced increase in
forearm 4). A significant effect of the drug was 
observed espite pretreatment with @‘-monomethyl+ 
arginine (p --z 0.01) (Fig. 4). No significant changes insystolic 
blwd pressure were found between the before and after states 
during this protocol (placebo, from 108 +- 6 to 104 5 3 mm Hg; 
en at, from 10s 2 4 to 105 +- 6 mm Hg). 
Of Phtmexbt with acetylsalicylic acid. There was 
no Significant effect of administration of acetylsalicylic acid on 
the forearm blood Ilow res 
Rgwre 2, Forearm ) responsss to ~~~~~~~~~line (AC@ 
) and with ion of the ungiotensin-converting 
inhibitor e t in control wbjects (Group 11, pntients 
heart faik ~~r~~~~ 2) and patients wit 
3). Data are mean value and 
Group 3 
RIS 
0 0.75 1.5 3.0 4.5 
Dose of ACh 1 n alminldl tissue) 
0 
re 3. Forearm blood flow (F 
(SNP) with (0) and withou 
responses to sodium nitroprus- 
) coinfusiola of the a~~io~e~s~~~ 
e inhibitor enalaprilat in control subjects (Group I), 
patients with mild heart failure (Goup 2) and patients with more 
advanced heart failure (Group 3). Data are mean v&e and SE. 
highest dose of acetylcholine, mean forearm blood Row was 
11.0 2 2.1 mllmin per 1 tissue for acetylcholine alone and 
9.4 9 1.4 mUmin per dl tissue for acetylcholine plus angioten- 
sin-converting eniym. inhibitor (p = NS) (Fig. 4). Systolic 
blood pressure did mot change during the course. of 
protocol (placebo, from 113 2 6 t 08 + 9 mm Hg; eraala 
lat, from 110 2 5 to 105 !I 8 m 
The mah obwvations of the present study are as follows: 1) 
Local intraarterial infusion of the angiotensin-converting e - 
zyme inhibitor enaiaprilat, producing a venous effluent con- 
centration comparable to that observed after oral administra- 
Forearm blood flow (F responses Lo acqkholinc (AC/n) 
after prelreatmerat with 
the a~giotensin-converting en2-y 
tional groups of patients with mil 
[bottom]). Basal acetykholine-r 
both groups is indicated by 
converiing enzyme inhibitor 
vasodilalory stimuli after 
blocked by pretreatment with ace@- 
a are mean value and SE. 
tion of the drug (17), was found to enhance peripheral 
endotheliurn-dependent vasodilation i duced by acetylcholine 
in bcalthy volunteers and patients with mild heart failure. 2) 
owever, this immediate ffect was not demonstrated during 
infusion of the endothelium-independent vasodilator sodium 
nitroprusside. 3) The ekxt of enalaprilat persisted espite 
pretreatment with the nitric oxide synthesis inhibitor fl- 
monomethyl-L-arginine butwas reduced after pretreatment 
with the cyclooxygenase inhibitor ace~~sa~icy~ic acid im 
ts. There was no significant corrc- 
plasma reniri activity or plasma ~ore~~~~~~~~~~~e concentra- 
tions. In addition, the potentiating effect of enalaprilat was not 
observed uring its combined administration with nitroprus- 
side, Because angiotensin-converting e zyme inhibitors timu- 
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late production or release of vasodilatory substances (i.e., 
bra&cnin, prostacyclin, e dothelium-derived relaxing factor) 
from the endothelium (18,19), the mechanism of the inhibitor’s 
enhancement of vasodilation may be attributable to the drug’s 
effect on vascular endothelial cehs. 
In the second protocol, pretreatment with No-monomethyl- 
r,.-arginine, which was reported elsewhere ($20) to be an 
effective inhibitor of nitric oxide synthesis, maintained the 
effect of enalaprilat in patients with chronic heart failure. This 
finding suggests that the observed effect is unlikely to occur 
through increased nitric oxide formation from the endothelial 
cells. In contrast, enalnprilat’s vasodilatory potentiating effect 
was diminished after pretreatment with the cyclooxygemase inhib- 
itor ~tylsalicylic a id, This observation may be consistent wi h a 
previous rqxm that an increase in forearm blood flow after oral 
administration of captopril was c~mpletcly b ocked after indo- 
methacin administration in patients with heart f&re 
imply indirectly that enalaprilat may be 
increased ndothelial synthesis or release of vasodilatory sub- 
stances facilitated through arachidonic acid bohsm. Further- 
more, because ace$&Mine has been su cd to stimulate 
~~~~~e~ndent endotheliumderived vasoconstricting 
factors (22), the inhibitors may reduce the etfects ofthe vasocon- 
strictor prostagfandins stimulated by acetylcholine. I  fact, angio- 
ten&r-converting e zyme inhibitors are known to 
bradykinin byinhibiting the converting enzyme, whit 
the peptide to inactive fragments. Several studies (23,24) have 
demonstrated thatan increase in bradykinin formation due to the 
enzyme inhibition will potentiate prostaglandin production. 
In contrast tothe present observation in patients with heart 
failure, we reported earlier (15) that he effect of enalaprilat 
in healthy voiunteers was inhibited by .~-monomethy~~~- 
arginine. The reasons for this discrepancy arc not yet known. 
However, in patients with chronic heart failure, there have 
everal reports (3-S) ing that production or 
of endothelial-derived laxhtg factor, which may 
be identical tonitric oxide, is decreased by~~~~inergi~ vasodi- 
hq stimuli, whereas prostaglnndin production from the 
endothelium has been reported (25,26) to be increased in
tknts with heart failure. These differences in the traits of 
dothelial utacoid formation i healthy subjects and patients 
with heart failure may underlie the diverse mechanisms by
which the enzyme inhibitors affect the peripheral vascular bed. 
In acxord win. *his hypothesis, JAmontagne et al. (27) recently 
reported that m rabbit coronary artery, acetylcholine and 
bradykinin stimulated the nitric oxide pathway rather than 
~i~~gena~-de~ndent vasodilatory prostaglandin u der 
normal conditions, whereas with nitric oxide pathway impair- 
ment, these substances significantly potentiate he effects of 
~~~~~~s. Endothelium has been suggested to 
play a pivotal role in the exercise-induced vasodilation medi- 
ated by endothelium-derived vasoactive substances. It may be 
likely that he restoration f impaired endothelium-dependent 
vasodilation may increase blood flow to working muscle and 
decrease cardiac afterload uring exercise in patients with 
heart failure. The in-mediate effect of e~a~a~ri~at on the 
peripheral vascular bed was not seen in advanced heart failure. 
Although we have been unable to account for this observa 
within the context of the present study. the followin 
explanations should be considered. First, the pbys 
of these patients may cause a~o~~te~ reduction 
blood flow and endothelial shear stress and may thus alter the 
metabolism or release ofendothelial vasodilato~ substances in 
this patient subgroup (28). Second, although no sig~i~ca~t 
peripheral edema was observed in t 
interstitial edema, engor 
arteriolar rn~r~b~~o~~c 
induced p~re~tiation of v~so~i~~ti~~. 
rematch that oral administration of c
increase inforearm blood flow in norma 
effect was obscMr~ 
tional class Z111). 
topril on the ~rogrcssi~l~ of heart fGlurc has been found to be 
higher among patients with a low fM~ctio~a1 cl ssi~c~~~on (33). 
Indeed, in some patients with heart Wilfred the ~~e~e~ci~~ 
clinical effects of the 
weeks. It should ther 
whether the obse~ed effect of the angiotensi~-converting 
enzyme inhibitor is reliable in the ~eri~herai as well as other 
vascular beds in the case of ~Q~~ter oral administration. 
Trudy ~j~~t~t~on§, It could not be determined from this 
study whether a~giotensin-convert’ nzyme i~bibitors gen- 
erally have the aforementioned reported. One must 
therefore be careful not to gen that these observed 
elFects are similar to what might be seen for all angiotensin- 
converting enzyme inhibitor. in isolated rat aortic ring, im- 
~rovement in e~doth~~ium-dependent vasodilation after 
chronic administration f angiotensin-converting elrzy
hibitors was found with captoprll but not with enalapril (12). 
However, inthe human peripheral vascular bed enalaprilat has 
sted to have a significant immediate effect on the 
metabolism of endothelium-dependent vasoactive substances 
(15,34). Inview of the long-acting pharmacologic character of
enalaprilat, experimental protocols were designed so that 
measurement of he control dose-response curves preceded 
the administration of enalaprilat plus acetylcholine. 
It has recently been demonstrated that basal forearm 
vascular tone is regulated by circadian sympathetic nerve 
activity in healthy subjects (35). Thus, the order in which the 
drugs were administered may have affected the results. How- 
ever, mean basal values were similar on each occasion before 
vasodilatory stimulation, and plasma norepinephrine levels did 
not change significantly before and after e~a~a~r~~at adminis- 
tration. it therefore seems unlikely that circadian variation i  
sympathetic tone activity would have had any significant effect 
on our findings. 
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